LINC02532 Contributes to Radiosensitivity in Clear Cell Renal Cell Carcinoma through the miR-654-5p/YY1 Axis

Xiaoguang Zhou1, Bowen Zeng1,2, Yansheng Li1

  • 1Department of Urology, Beijing Chaoyang Hospital, Capital Medical University, Beijing 100020, China.

Abstract

Insights

This study reveals a LINC02532/miR-654-5p/YY1 feedback loop enhances clear cell renal cell carcinoma (ccRCC) radioresistance. Targeting LINC02532 could improve ccRCC radiotherapy outcomes.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Long non-coding RNAs (lncRNAs) are implicated in tumor progression and radiotherapy response in clear cell renal cell carcinoma (ccRCC).
  • LINC02532 is upregulated in ccRCC, but its specific role, particularly in radioresistance, remains largely uncharacterized.

Purpose of the Study:

  • To investigate the functional role of LINC02532 in ccRCC radioresistance.
  • To elucidate the molecular mechanism underlying LINC02532's regulation of ccRCC radiosensitivity.

Main Methods:

  • Quantitative real-time PCR and Western blotting to assess expression levels of LINC02532, miR-654-5p, and YY1.
  • Clonogenic survival, CCK-8, and flow cytometry assays to evaluate cell radiosensitivity, viability, and apoptosis.
  • Chromatin immunoprecipitation, dual-luciferase reporter assays, and in vivo xenograft models to determine the regulatory network and in vivo effects.

Main Results:

  • LINC02532 expression was high in ccRCC cells and increased post-irradiation, correlating with radioresistance.
  • LINC02532 knockdown significantly enhanced ccRCC cell radiosensitivity both in vitro and in vivo.
  • A positive feedback loop involving YY1 activating LINC02532, and LINC02532 sponging miR-654-5p to regulate YY1, was identified.

Conclusions:

  • A novel LINC02532/miR-654-5p/YY1 positive feedback loop critically regulates ccRCC radioresistance.
  • LINC02532 emerges as a potential therapeutic target to enhance the efficacy of radiotherapy for ccRCC.
  • This study provides a foundation for further research into LINC02532's role in ccRCC and other cancers.